No Data
Toronto Stocks Flat as Liberals Clinch Fourth Term Government; Profound Medical Shares Up
Lake Street Maintains Profound Medical(PROF.US) With Buy Rating, Maintains Target Price $11
Lake Street Sticks to Its Buy Rating for Profound Medical (PRN)
Profound Medical Says Peri-operative Study Backs TULSA Procedure Effectiveness
Profound Medical Announces Initial Perioperative Data From Level 1 Post-Market CAPTAIN Trial Comparing Safety, Efficacy Of TULSA Procedure With RP In Men With Gleason Score 7 Prostate Cancer
Profound Medical Brief: Says Provides "Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy"